Table 3.
Risk analysis in survivors and non-survivor MISC patients.
| Data | Non-survivors | Survivors | p | OR (IC95) |
|---|---|---|---|---|
| N = 3 | N = 31 | |||
| Sex | ||||
| Male n (%) | 1 (33.33) | 17 (54.84) | Ref. | 1 |
| Female n (%) | 2 (66.67) | 14 (45.16) | 0.59 | 0.41 (0.03–5.03) |
| AGE (month) | ||||
| Median (R.I) | 11.0 (8.5–10.7.5) | 75.0 (12.0–126.0) | 1 | INF |
| Previos medical history | ||||
| Yes n (%) | 2 (66.67) | 2 (6.45) | 0.06 | 22.88 (0.88–1,765) |
| Origin | ||||
| Huila n (%) | 3 (100) | 24 (77.42) | 0.49 | - |
| Cardiopulmonary condition n (%) | ||||
| Systolic dysfunction | 2 (66.67) | 10 (32.26) | 0.28 | 4.2 (0.40–51.98) |
| Diastolic dysfunction | 3 (100) | 7 (22.58) | 0.02 | - |
| Pericardial effusion | 3 (100) | 6 (19.35) | 0.01 | - |
| Pulmonary hypertension | 1 (33.33) | 2 (6.45) | 0.25 | 7.25 (0.44–118.70) |
| Atrial dilation | 1 (33.33) | 3 (9.68) | 0.32 | 4.67 (0.32–68.03) |
| Ventricular dilation | 2 (66.67) | 4 (12.90) | 0.07 | 13.5 (0.98–185.45) |
| Ejection fraction | ||||
| Median (r.i) | 59.0 (45.0–62.0) | 65.0 (57.5–68.5) | 0.2 | INF |
| Shortening fraction | ||||
| Median (r.i) | 31.0 (21.0–32.5) | 33.0 (30.0–37.0) | 0.25 | INF |
| Dyskinesia | ||||
| Yes n (%) | 0 | 9 (29.03) | 0.55 | - |
| Shock | ||||
| Yes n (%) | 3 (100) | 19 (61.29) | 0.54 | - |
| Arrhythmia | ||||
| Yes n (%) | 3 (100) | 8 (25.81) | 0.03 | - |
| Coronary involvement n (%) | ||||
| No | 2 (66.67) | 18 (58.06) | ref. | 1 |
| Yes | 1 (33.33) | 13 (41.94) | 0.82 | 0.70 (0.02–10.04) |
| Leukocytes/mcl | 13,100 | 14,290 | ||
| median (i.r) | (8,345–26,550) | (8,085–19,480) | 0.95 | INF |
| Neutrophils /mcl | 7,700 | 9,880 | 0.95 | INF |
| median (i.r) | (4,815–16,150) | (4,456–13,925) | ||
| Lymphocytes /mcl | 1,220 | 2,150 | 0.45 | INF |
| median (i.r) | (950–2,240) | (1,145–3,691) | ||
| Hemoglobin g/dl | 9.1 | 11.4 | 0.25 | INF |
| median (i.r) | (8.85–10.25) | (9.25–1,290) | ||
| Hematocrit % | 27.8 | 33.8 | ||
| median (i.r) | (27.65–32.55) | (29.25–38.45) | 0.4 | INF |
| ESR mm/h | ||||
| median (i.r) | 21.0 (19.50–23.0) | 32.0 (22.0–44.0) | 0.15 | INF |
| CRPmg/dl | ||||
| median (i.r) | 9.0 (4.75–9.40) | 9.0 (3.31–24.72) | 0.43 | INF |
| PCT ng/ml | ||||
| median (i.r) | 4.79 (2.44–33.64) | 1.47 (0.36–3.59) | 0.67 | INF |
| GOT U/L | ||||
| median (i.r) | 109.0 (87.50–3,804.50) | 32.10 (23.15–53.0) | 0.02 | INF |
| GPTU/L | ||||
| median (i.r) | 32.7 (25.35–2,126.85) | 20.0 (12.50–41.50) | 0.3 | INF |
| DHL U/L | ||||
| mediana (i.r) | 832.0 (644.0–1,483.0) | 296.5 (228.5–360.0) | 0.02 | INF |
| UNB mg/dl | ||||
| median (i.r) | 57.0 (33.5–88.5) | 9.0 (5.32–12.0) | 0.04 | INF |
| Troponin ng/ml | ||||
| median (i.r) | 0.05 (0.04–0.63) | 0.15 (0.09–0.33) | 0.76 | INF |
| Albumin g/dl | ||||
| median (i.r) | 2.51 (2.21–2.96) | 2.91 (2.60–3.32) | 0.35 | INF |
i.r, interquartile range; OR, odds ratio; GSR, globular sedimentation rate; CRP C, reactive protein; PCT, procalcitonin; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; LDH, lactic dehydrogens; UNB, urea nitrogen in blood, ESR, erythrocyte sedimentation rate; Mcl, microliter; INF, values are infinite.